Experimed

SUBMITINFORMATION
EnglishTürkçe

Editorial


DOI :10.26650/experimed.1404013   IUP :10.26650/experimed.1404013    Full Text (PDF)

Artificial Intelligence-Enhanced Application of CRISPR-Cas13a for Cancer Gene Therapy: A Breakthrough Concept

Tungki Pratama Umar


PDF View

References

  • Roma-Rodrigues C, Rivas-Garaa L, Baptista PV, Fernandes AR. Gene therapy in cancer treatment: why go nano? Pharmaceutics 2020; 12(3): 233. google scholar
  • Rao K. CRISPR-Cas13 and its applications in human therapeutics. J High Sch Sci 2021; 5(4): 1-21. google scholar
  • Granados-Riveron JT, Aquino-Jarquin G. CRISPR-Cas13 precision transcriptome engineering in cancer. Cancer Res 2018; 78(15): 4107-13. google scholar
  • Gao J, Luo T, Lin N, Zhang S, Wang J. A new tool for CRISPR-Cas13a-based cancer gene therapy. Mol Ther Oncolytics 2020; 19: 79-92. google scholar

Citations

Copy and paste a formatted citation or use one of the options to export in your chosen format


EXPORT



APA

Umar, T.P. (2024). Artificial Intelligence-Enhanced Application of CRISPR-Cas13a for Cancer Gene Therapy: A Breakthrough Concept. Experimed, 14(1), 61-62. https://doi.org/10.26650/experimed.1404013


AMA

Umar T P. Artificial Intelligence-Enhanced Application of CRISPR-Cas13a for Cancer Gene Therapy: A Breakthrough Concept. Experimed. 2024;14(1):61-62. https://doi.org/10.26650/experimed.1404013


ABNT

Umar, T.P. Artificial Intelligence-Enhanced Application of CRISPR-Cas13a for Cancer Gene Therapy: A Breakthrough Concept. Experimed, [Publisher Location], v. 14, n. 1, p. 61-62, 2024.


Chicago: Author-Date Style

Umar, Tungki Pratama,. 2024. “Artificial Intelligence-Enhanced Application of CRISPR-Cas13a for Cancer Gene Therapy: A Breakthrough Concept.” Experimed 14, no. 1: 61-62. https://doi.org/10.26650/experimed.1404013


Chicago: Humanities Style

Umar, Tungki Pratama,. “Artificial Intelligence-Enhanced Application of CRISPR-Cas13a for Cancer Gene Therapy: A Breakthrough Concept.” Experimed 14, no. 1 (Dec. 2024): 61-62. https://doi.org/10.26650/experimed.1404013


Harvard: Australian Style

Umar, TP 2024, 'Artificial Intelligence-Enhanced Application of CRISPR-Cas13a for Cancer Gene Therapy: A Breakthrough Concept', Experimed, vol. 14, no. 1, pp. 61-62, viewed 21 Dec. 2024, https://doi.org/10.26650/experimed.1404013


Harvard: Author-Date Style

Umar, T.P. (2024) ‘Artificial Intelligence-Enhanced Application of CRISPR-Cas13a for Cancer Gene Therapy: A Breakthrough Concept’, Experimed, 14(1), pp. 61-62. https://doi.org/10.26650/experimed.1404013 (21 Dec. 2024).


MLA

Umar, Tungki Pratama,. “Artificial Intelligence-Enhanced Application of CRISPR-Cas13a for Cancer Gene Therapy: A Breakthrough Concept.” Experimed, vol. 14, no. 1, 2024, pp. 61-62. [Database Container], https://doi.org/10.26650/experimed.1404013


Vancouver

Umar TP. Artificial Intelligence-Enhanced Application of CRISPR-Cas13a for Cancer Gene Therapy: A Breakthrough Concept. Experimed [Internet]. 21 Dec. 2024 [cited 21 Dec. 2024];14(1):61-62. Available from: https://doi.org/10.26650/experimed.1404013 doi: 10.26650/experimed.1404013


ISNAD

Umar, TungkiPratama. “Artificial Intelligence-Enhanced Application of CRISPR-Cas13a for Cancer Gene Therapy: A Breakthrough Concept”. Experimed 14/1 (Dec. 2024): 61-62. https://doi.org/10.26650/experimed.1404013



TIMELINE


Submitted12.12.2023
Accepted05.02.2024
Published Online25.03.2024

LICENCE


Attribution-NonCommercial (CC BY-NC)

This license lets others remix, tweak, and build upon your work non-commercially, and although their new works must also acknowledge you and be non-commercial, they don’t have to license their derivative works on the same terms.


SHARE




Istanbul University Press aims to contribute to the dissemination of ever growing scientific knowledge through publication of high quality scientific journals and books in accordance with the international publishing standards and ethics. Istanbul University Press follows an open access, non-commercial, scholarly publishing.